Kyntra Bio KYNB 深 滬
等待開盤 11-04 09:30:00 美东时间
4.31
-0.150
-3.36%
華盛通- 最 高4.51
- 今 開4.46
- 成交量 2.21万股
- 最 低 4.24
- 昨 收 4.46
- 總市值 1745.17万
- 52周最高 11.1899
- 市盈率 靜 0.10
- 換手率 0.55%
- 52周最低 4.24
- 委 比 -63.93%
- 總股本 404.91万
- 歷史最高 1713.75
- 量 比 1.31
- 振 幅 6.05%
- 歷史最低 4.24
- 每 手 1
- 風險率 1.17%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Maxim Group Initiates Coverage On Kyntra Bio with Buy Rating, Announces Price Target of $35
Maxim Group analyst Michael Okunewitch initiates coverage on Kyntra Bio (NASDAQ:KYNB) with a Buy rating and announces Price Target of $35.
10-14 04:25
Kyntra Bio Appoints Andrew E. Singer, MBA to its Board of Directors
Kyntra Bio announced the appointment of Andrew E. Singer, MBA, to its Board of Directors as an independent director and member of the Audit Committee effective October 1, 2026. Maykin Ho, Ph.D., has stepped down from the Board after nearly eight years of service. Singer brings over 25 years of experience in biotechnology finance, corporate strategy, and public company leadership. He currently serves as Founder and CEO of Fika Bio Consulting, Inc....
10-01 11:00
美股大行评级 | 赛富时获多家机构上调目标价，最高至300美元！谷歌获看多至450美元，仍有3成上涨空间
今日重点评级关注：Canaccord Genuity：维持Generac Holdings"买入"评级，目标价从275美元升至375美元；巴克莱：维持Oscar Health"超配"评级，目标价从39美元升至49美元
09-18 16:18
Lake Street Initiates Coverage On Kyntra Bio with Buy Rating, Announces Price Target of $41
Lake Street analyst Daniel Brims initiates coverage on Kyntra Bio (NASDAQ:KYNB) with a Buy rating and announces Price Target of $41.
09-17 21:12
美股大行评级 | 美银上调微软目标价从500美元升至600美元；BlossomHill获小摩等多家大行首予买入评级
今日重点评级关注：BTIG：维持Kazia Therapeutics"买入"评级，目标价从34美元升至40美元；摩根大通：维持Annexon"超配"评级，目标价从10美元升至14美元
09-02 14:07
HC Wainwright & Co. Reiterates Buy on Kyntra Bio, Maintains $43 Price Target
HC Wainwright & Co. analyst Matthew Keller reiterates Kyntra Bio (NASDAQ:KYNB) with a Buy and maintains $43 price target.
09-01 18:26
Kyntra Bio Streamlines Financing, Strengthens Balance Sheet
Kyntra Bio ( ($KYNB) ) has shared an update. On August 31, 2026, Kyntra Bio ame...
09-01 05:52
Kyntra Bio Continues Balance Sheet Transformation with Material Reduction of Royalty Financing Obligation
Kyntra Bio amended its royalty financing agreement with NQ Project Phoebus, L.P., reducing maximum payments from $125 million to $65 million. The company made a $42.6 million accelerated upfront payment, returning NQ's invested capital, with up to $15 million in additional payments. Remaining payments are capped at $15 million, sourced from 50% of revenue from Astellas territories excluding Japan. The amendment strengthens Kyntra's financial posi...
08-31 20:05
UPDATE: Kyntra Bio Q2 Adj. EPS $(4.68) Misses $(3.18) Estimate, Sales $(1.474M) Miss $2.007M Estimate
Kyntra Bio (NASDAQ:KYNB) reported quarterly losses of $(4.68) per share which missed the analyst consensus estimate of $(3.18) by 47.17 percent. This is a 148.94 percent decrease over losses of $(1.88) per share from the same period last year. The company reported quarterly sales of $(1.474 million)...
08-14 06:07
